'Secondary' acute lymphoblastic/lymphocytic leukemia - done playing second fiddle?
Yosef Joseph Rene Amel Riazat-Kesh1, John Mascarenhas2, Michal Bar-Natan2
1Icahn School of Medicine Mount Sinai West and Morningside, 1000 Tenth Avenue, New York, NY 10019, United States of America.
Blood Reviews
|March 9, 2023
Summary
Secondary acute lymphoblastic leukemia (sALL) is a distinct entity in cancer survivors, comprising 5-10% of ALL diagnoses. Research explores its unique biology, causes, and treatment implications.
Area of Science:
- Hematology
- Oncology
- Cancer Research
Background:
- Secondary acute lymphoblastic leukemia (sALL) is increasingly recognized as a distinct clinical entity.
- It constitutes 5-10% of all new acute lymphoblastic leukemia (ALL) diagnoses.
- sALL carries unique biologic, prognostic, and therapeutic significance compared to de novo ALL.
Purpose of the Study:
- To review the history and current research landscape of sALL.
- To explore evidence supporting sALL as a distinct subgroup.
- To examine potential etiological drivers, including prior chemotherapy, and their impact.
Main Methods:
- Review of existing literature on sALL.
- Analysis of population-, chromosomal-, and molecular-level distinctions.
- Evaluation of clinical outcomes and treatment strategies for sALL.
Main Results:
- Evidence suggests sALL differs from de novo ALL at multiple levels.
- Prior chemotherapy is a potential etiological factor.
- Distinctions may translate to differences in clinical outcomes and treatment selection.
Conclusions:
- sALL represents a unique leukemia subtype requiring further investigation.
- Understanding its distinct characteristics is crucial for optimizing patient care.
- Further research may inform tailored treatment approaches for sALL patients.
Keywords:
ALLAcute lymphoblastic leukemiaAcute lymphocytic leukemiaPrior malignancy acute lymphoblastic leukemiaSecondary acute lymphoblastic leukemiaSecondary leukemiaTherapy-related acute lymphoblastic leukemiapmALLsALLtALL
